The post-exposure treatment made with antibodies from horses could be used in the next Ebola outbreak, researchers said.
"This is a cost-effective treatment that can be used in low-income countries in Africa where equine production facilities are already in operation for producing snake-bite antivenin," said Alexander Khromykh, Professor at University of Queensland (UQ) in Australia.
"It's the first time that equine antibodies have been shown to work effectively against Ebola infection," Khromykh said.
The largest recorded outbreak of Ebola virus occurred primarily in West Africa from 2014 to 2016, infecting 30,000 people and killing more than 11,000, with exported cases in Europe and North America.
"The down side is that monoclonal antibodies require considerable investment for scale-up and manufacture, and are expensive," Khromykh said.
"Equine antibodies are a considerably cheaper alternative, with manufacturing capacity already in place in Africa.
"Antibodies from vaccinated horses provide a low-cost alternative, and are already in use for rabies, botulism and diphtheria," he said.
Professor Paul Young, who was part of the UQ research team, said the finding offered great hope as a rapid treatment option for Ebola patients.
"It is also a far more appropriate option for resource-poor settings," he said.
Khromykh's team has previously developed an experimental Ebola vaccine made using an Australian virus called Kunjin, that might also help in the fight against the deadly Ebola virus.
The research was published in the journal Scientific Reports.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
